ArriVent BioPharma, Inc. (AVBP)
AVBP Stock Price Chart
Explore ArriVent BioPharma, Inc. interactive price chart. Choose custom timeframes to analyze AVBP price movements and trends.
AVBP Company Profile
Discover essential business fundamentals and corporate details for ArriVent BioPharma, Inc. (AVBP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Jan 2024
Employees
77.00
Website
https://arrivent.comCEO
Zhengbin Yao
Description
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
AVBP Financial Timeline
Browse a chronological timeline of ArriVent BioPharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.98.
Earnings released on 11 May 2026
EPS came in at -$0.96 falling short of the estimated -$0.88 by -9.09%.
Earnings released on 5 Mar 2026
EPS came in at -$0.78 surpassing the estimated -$0.87 by +10.34%.
Earnings released on 10 Nov 2025
EPS came in at -$0.83 falling short of the estimated -$0.78 by -6.41%.
Earnings released on 11 Aug 2025
EPS came in at -$0.90 falling short of the estimated -$0.70 by -28.57%.
Earnings released on 12 May 2025
EPS came in at -$1.90 falling short of the estimated -$0.66 by -187.88%.
Earnings released on 3 Mar 2025
EPS came in at -$0.60 surpassing the estimated -$0.78 by +23.08%.
Earnings released on 14 Nov 2024
EPS came in at -$0.61 surpassing the estimated -$0.82 by +25.61%.
Earnings released on 14 Aug 2024
EPS came in at -$0.65 matching the estimated -$0.65.
Earnings released on 8 May 2024
EPS came in at -$0.70 surpassing the estimated -$0.84 by +16.67%.
Earnings released on 26 Jan 2024
EPS came in at -$0.70 surpassing the estimated -$1.10 by +36.36%.
Earnings released on 30 Sept 2023
EPS came in at -$0.43 .
Earnings released on 30 Jun 2023
EPS came in at -$0.64 .
Earnings released on 31 Mar 2023
EPS came in at -$0.36 .
Earnings released on 30 Dec 2022
EPS came in at -$0.31 .
Earnings released on 29 Sept 2022
EPS came in at -$0.35 .
Earnings released on 30 Jun 2022
EPS came in at -$5.76 .
Earnings released on 31 Mar 2022
EPS came in at -$5.76 .
AVBP Stock Performance
Access detailed AVBP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
